JP2010503731A - 肺サーファクタント製剤および粘液クリアランスの促進方法 - Google Patents

肺サーファクタント製剤および粘液クリアランスの促進方法 Download PDF

Info

Publication number
JP2010503731A
JP2010503731A JP2009529215A JP2009529215A JP2010503731A JP 2010503731 A JP2010503731 A JP 2010503731A JP 2009529215 A JP2009529215 A JP 2009529215A JP 2009529215 A JP2009529215 A JP 2009529215A JP 2010503731 A JP2010503731 A JP 2010503731A
Authority
JP
Japan
Prior art keywords
surfactant
patient
pulmonary
amino acid
pulmonary surfactant
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2009529215A
Other languages
English (en)
Japanese (ja)
Other versions
JP2010503731A5 (enExample
Inventor
マーク・イー・ジョンソン
ロバート・シーガル
トーマス・ホフマン
ロバート・ジェイ・カペトラ
Original Assignee
ディスカバリー ラボラトリーズ，インコーポレイテッド
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by ディスカバリー ラボラトリーズ，インコーポレイテッド filed Critical ディスカバリー ラボラトリーズ，インコーポレイテッド
Publication of JP2010503731A publication Critical patent/JP2010503731A/ja
Publication of JP2010503731A5 publication Critical patent/JP2010503731A5/ja
Pending legal-status Critical Current

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/66—Phosphorus compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/007—Pulmonary tract; Aromatherapy
    • A61K9/0073—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy
    • A61K9/0078—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy for inhalation via a nebulizer such as a jet nebulizer, ultrasonic nebulizer, e.g. in the form of aqueous drug solutions or dispersions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A61K9/12—Aerosols; Foams
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/02—Nasal agents, e.g. decongestants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/10—Expectorants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/12—Mucolytics

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pulmonology (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Dispersion Chemistry (AREA)
  • Otolaryngology (AREA)
  • Immunology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Peptides Or Proteins (AREA)
JP2009529215A 2006-09-19 2007-09-19 肺サーファクタント製剤および粘液クリアランスの促進方法 Pending JP2010503731A (ja)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US84599106P 2006-09-19 2006-09-19
PCT/US2007/020260 WO2008036293A1 (en) 2006-09-19 2007-09-19 Pulmonary surfactant formulations and methods for promoting mucus clearance

Publications (2)

Publication Number Publication Date
JP2010503731A true JP2010503731A (ja) 2010-02-04
JP2010503731A5 JP2010503731A5 (enExample) 2010-11-11

Family

ID=38921793

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2009529215A Pending JP2010503731A (ja) 2006-09-19 2007-09-19 肺サーファクタント製剤および粘液クリアランスの促進方法

Country Status (11)

Country Link
US (1) US8221772B2 (enExample)
EP (1) EP2063903A1 (enExample)
JP (1) JP2010503731A (enExample)
KR (1) KR20090060348A (enExample)
AU (1) AU2007297691B2 (enExample)
BR (1) BRPI0717177A2 (enExample)
CA (1) CA2663795A1 (enExample)
MX (1) MX2009003002A (enExample)
RU (1) RU2455021C2 (enExample)
WO (1) WO2008036293A1 (enExample)
ZA (1) ZA200902487B (enExample)

Cited By (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2013540704A (ja) * 2010-08-23 2013-11-07 タケダ ゲゼルシャフト ミット ベシュレンクテル ハフツング 治療学的に有効な物質を含む加湿された粒子
JP2017222717A (ja) * 2011-06-07 2017-12-21 パリオン・サイエンシィズ・インコーポレーテッド 治療の方法
JP2019203001A (ja) * 2014-08-08 2019-11-28 シンセン ハイタイド バイオファーマシューティカル リミテッド 液体製剤組成物、薬物送達デバイス、ならびにそれらの調製および使用の方法

Families Citing this family (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8669418B2 (en) 2005-12-22 2014-03-11 Vib Vzw Means and methods for mediating protein interference
WO2009049159A1 (en) 2007-10-10 2009-04-16 Parion Sciences, Inc. Delivering osmolytes by nasal cannula
EA022786B1 (ru) 2009-07-31 2016-03-31 Этрис Гмбх Рнк с комбинацией из немодифицированных и модифицированных нуклеотидов для экспрессии белков
US8945605B2 (en) 2011-06-07 2015-02-03 Parion Sciences, Inc. Aerosol delivery systems, compositions and methods
WO2015061412A1 (en) * 2013-10-22 2015-04-30 The Scripps Research Institute Methods and compositions for promoting bronchioli dilatation
GB201406225D0 (en) * 2014-04-07 2014-05-21 Hall Roderick L Treatment for respiratory disease
US12702649B2 (en) * 2016-05-23 2026-08-11 University Of Iowa Research Foundation Method of treating cystic fibrosis airway disease
EP3484458A4 (en) * 2016-07-16 2020-04-15 Lauranell Harrison Burch METHOD FOR TREATING MUCOVISCIDOSIS AND OTHER DISEASES WITH EFFECT ON THE MUCOSA
US11096932B2 (en) 2016-09-29 2021-08-24 The Uab Research Foundation Methods and compositions for increasing mucus clearance
EP3621979A1 (en) 2017-05-09 2020-03-18 VIB vzw Means and methods for treating bacterial infections
MX2020006634A (es) * 2017-12-21 2021-01-15 Civitas Therapeutics Inc Formulaciones de surfactantes para inhalacion.
US12427273B1 (en) 2020-05-15 2025-09-30 John E. Boyd Methods for treating respiratory distress and compositions for use in the same
GB202202297D0 (en) 2022-02-21 2022-04-06 Verona Pharma Plc Formulation production process
CN121620356A (zh) 2023-06-26 2026-03-06 维罗纳制药公司 包含恩塞芬汀的颗粒组合物
KR20250153517A (ko) 2024-04-18 2025-10-27 민현홍 신생아 호흡 곤란 증후군을 앓고 있는 조산아의 폐 전달을 개선하기 위한 미세기포 함유 에어로졸
WO2025231023A1 (en) * 2024-04-29 2025-11-06 Virginia Commonwealth University Aerosol surfactant therapy (ast) for respiratory distress syndrome (rds)

Citations (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPH06508619A (ja) * 1991-06-14 1994-09-29 ザ スクリップス リサーチ インスティテュート 合成肺界面活性ペプチド
JPH10316587A (ja) * 1997-04-28 1998-12-02 Scripps Res Inst:The 希釈した界面活性物質を含有する肺胞洗浄用医薬組成物
JP2002532558A (ja) * 1998-12-22 2002-10-02 バイエル アクチェンゲゼルシャフト 粘膜線毛クリアランスの速度を促進する方法
WO2005055994A1 (en) * 2003-12-04 2005-06-23 The Scripps Research Institute Treatment and preventions of asthma
WO2005115520A1 (en) * 2004-05-20 2005-12-08 Discovery Laboratories, Inc. Methods , systems and devices for noninvasive pulmonary delivery
WO2006013183A1 (en) * 2004-08-06 2006-02-09 Altana Pharma Ag Composition comprising a pulmonary surfactant and a tnf-derived peptide
WO2006071796A2 (en) * 2004-12-23 2006-07-06 Discovery Laboratories, Inc. Pulmonary surfactant formulations
WO2006074296A1 (en) * 2005-01-06 2006-07-13 Discovery Laboratories, Inc. Surfactant treatment regimen for treating or preventing bronchopulmonary dysplasia

Family Cites Families (36)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5840527A (en) 1984-12-11 1998-11-24 Byk Gulden Lomberg Chemische Fabrik Gmbh Recombinant alveolar surfactant protein
US4659805A (en) 1984-12-11 1987-04-21 California Biotechnology, Inc. Recombinant alveolar surfactant protein
US4918161A (en) 1985-09-26 1990-04-17 Genetics Institute, Inc. Low molecular weight pulmonary surfactant proteins
IT1203873B (it) 1987-04-08 1989-02-23 Chiesi Farma Spa Composizioni farmaceutiche che lo surfattante polmonare naturale, contengono. metodo di preparazione e
AU625394B2 (en) 1987-11-04 1992-07-09 Byk Gulden Lomberg Chemische Fabrik Gmbh Alveolar surfactant proteins
US5164369A (en) 1988-01-06 1992-11-17 The Scripps Research Institute Pulmonary surfactant protein and related polypeptide
US6613734B2 (en) 1988-01-06 2003-09-02 The Scripps Research Institute Peptides-containing liposomal surfactants
US4861756A (en) 1988-03-08 1989-08-29 Merrell Dow Pharmaceuticals Inc. Synthetic pulmonary surfactant
SE8803713D0 (sv) 1988-10-18 1988-10-18 Kabigen Ab Biologically active lipoprotein and its use
US5006343A (en) 1988-12-29 1991-04-09 Benson Bradley J Pulmonary administration of pharmaceutically active substances
US5238920A (en) 1989-08-22 1993-08-24 Abbott Laboratories Pulmonary surfactant protein fragments
EP0458167B1 (en) 1990-05-21 1997-04-23 Abbott Laboratories Fatty acid-pulmonary surfactant conjugates
US5272252A (en) 1991-11-04 1993-12-21 Merrell Dow Pharmaceuticals Inc. Synthetic lung surfactant having antioxidant properties
WO1993021221A1 (en) 1992-04-10 1993-10-28 Abbott Laboratories Pulmonary surfactant protein fragments
US5302481A (en) 1993-06-07 1994-04-12 Xerox Corporation Toner compositions with negative charge enhancing complexes
ES2189825T3 (es) 1993-12-08 2003-07-16 Mitsubishi Pharma Corp Nuevo peptido sintetico, tensioactivo pulmonar que lo contiene y remedio para el sindrome de malestar respiratorio.
DE4418936A1 (de) 1994-05-31 1996-02-08 Byk Gulden Lomberg Chem Fab Polypeptid
DE4434629C1 (de) 1994-09-28 1996-06-27 Byk Gulden Lomberg Chem Fab Zusammensetzungen zur Behandlung von IRDS und ARDS
US5508269A (en) 1994-10-19 1996-04-16 Pathogenesis Corporation Aminoglycoside formulation for aerosolization
US5767068A (en) 1997-02-13 1998-06-16 Pathogenesis Corporation Pure biologically active colistin, its components and a colistin formulation for treatment of pulmonary infections
US5925334A (en) 1997-08-27 1999-07-20 Rubin; Bruce K. Use of surface active agents to promote mucus clearance
US7198635B2 (en) * 2000-10-17 2007-04-03 Asthmatx, Inc. Modification of airways by application of energy
US6926911B1 (en) 1998-12-22 2005-08-09 The University Of North Carolina At Chapel Hill Compounds and methods for the treatment of airway diseases and for the delivery of airway drugs
RU2149014C1 (ru) 1999-07-01 2000-05-20 Центральный научно-исследовательский рентгенорадиологический институт Способ лечения острых бронхопневмоний, осложненных ателектазом
RU2149015C1 (ru) * 1999-07-01 2000-05-20 Центральный научно-исследовательский рентгенорадиологический институт Способ лечения постнатальных пневмоний у новорожденных
DE10006179A1 (de) 2000-02-11 2001-08-23 Byk Gulden Lomberg Chem Fab Neue Verwendung von Lungensurfactant zur Prophylaxe und Behandlung von chronischen Lungenerkrankungen
US6660833B1 (en) 2000-02-29 2003-12-09 Harbor-Ucla Research And Education Institute Respiratory distress syndrome therapy with peptide analogs of human SP-B
US7422743B2 (en) * 2000-05-10 2008-09-09 Schering Corporation Mammalian receptor protein DCRS5;methods of treatment
PT1280520E (pt) * 2000-05-10 2014-12-16 Novartis Ag Pós à base de fosfolípidos para administração de fármacos
EP1238680B1 (en) 2001-03-05 2003-12-10 Ivo Pera Inhaling device for dispersing powdered medicaments contained in a capsule through the respiratory tract
CA2445516C (en) 2001-04-26 2007-11-20 New England Pharmaceuticals, Inc. Metered dose delivery device for liquid and powder agents
RU2213746C1 (ru) 2002-02-15 2003-10-10 Научно-исследовательский институт физико-химической медицины Компонент, обеспечивающий поверхностно-активные свойства композиций - аналогов препаратов для заместительной сурфактантной терапии легочных заболеваний
RU2198670C1 (ru) 2002-02-19 2003-02-20 ООО "Биосурф" Способ получения сурфактанта из легких крупного рогатого скота
GB0327723D0 (en) * 2003-09-15 2003-12-31 Vectura Ltd Pharmaceutical compositions
JP2008511398A (ja) 2004-08-27 2008-04-17 ディスカバリー ラボラトリーズ，インコーポレイテッド 非侵襲性肺送出のための方法、システム及び装置
US7582312B2 (en) * 2004-11-15 2009-09-01 Discovery Laboratories, Inc. Methods to produce lung surfactant formulations via lyophilization and formulations and uses thereof

Patent Citations (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPH06508619A (ja) * 1991-06-14 1994-09-29 ザ スクリップス リサーチ インスティテュート 合成肺界面活性ペプチド
JPH10316587A (ja) * 1997-04-28 1998-12-02 Scripps Res Inst:The 希釈した界面活性物質を含有する肺胞洗浄用医薬組成物
JP2002532558A (ja) * 1998-12-22 2002-10-02 バイエル アクチェンゲゼルシャフト 粘膜線毛クリアランスの速度を促進する方法
WO2005055994A1 (en) * 2003-12-04 2005-06-23 The Scripps Research Institute Treatment and preventions of asthma
WO2005115520A1 (en) * 2004-05-20 2005-12-08 Discovery Laboratories, Inc. Methods , systems and devices for noninvasive pulmonary delivery
WO2006013183A1 (en) * 2004-08-06 2006-02-09 Altana Pharma Ag Composition comprising a pulmonary surfactant and a tnf-derived peptide
WO2006071796A2 (en) * 2004-12-23 2006-07-06 Discovery Laboratories, Inc. Pulmonary surfactant formulations
WO2006074296A1 (en) * 2005-01-06 2006-07-13 Discovery Laboratories, Inc. Surfactant treatment regimen for treating or preventing bronchopulmonary dysplasia

Cited By (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2013540704A (ja) * 2010-08-23 2013-11-07 タケダ ゲゼルシャフト ミット ベシュレンクテル ハフツング 治療学的に有効な物質を含む加湿された粒子
US9693955B2 (en) 2010-08-23 2017-07-04 Fraunhofer-Gesellschaft zur Förderung der angewandten Forschung e.V. Humidified particles comprising a therapeutically active substance
JP2017222717A (ja) * 2011-06-07 2017-12-21 パリオン・サイエンシィズ・インコーポレーテッド 治療の方法
JP2019203001A (ja) * 2014-08-08 2019-11-28 シンセン ハイタイド バイオファーマシューティカル リミテッド 液体製剤組成物、薬物送達デバイス、ならびにそれらの調製および使用の方法

Also Published As

Publication number Publication date
WO2008036293A1 (en) 2008-03-27
CA2663795A1 (en) 2008-03-27
ZA200902487B (en) 2010-07-28
MX2009003002A (es) 2009-06-01
AU2007297691B2 (en) 2013-12-19
BRPI0717177A2 (pt) 2013-10-08
RU2009114825A (ru) 2010-10-27
US8221772B2 (en) 2012-07-17
US20080199410A1 (en) 2008-08-21
EP2063903A1 (en) 2009-06-03
KR20090060348A (ko) 2009-06-11
RU2455021C2 (ru) 2012-07-10
AU2007297691A1 (en) 2008-03-27

Similar Documents

Publication Publication Date Title
AU2007297691B2 (en) Pulmonary surfactant formulations and methods for promoting mucus clearance
JP5666569B2 (ja) サーファクタントタンパク質ｂ（ｓｐ−ｂ）およびサーファクタントタンパク質ｃ（ｓｐ−ｃ）の類似体を含有する改善された再構築サーファクタント組成物
US8337815B2 (en) Pulmonary surfactant formulations
CN101687006A (zh) 具有改善特性的重建表面活性剂
JP2013177422A (ja) サーファクタント処置療法
BR112015009486B1 (pt) Surfactante reconstituído, formulação farmacêutica, kit e uso de surfactante reconstituído
Walther et al. Aerosol delivery of lung surfactant and nasal CPAP in the treatment of neonatal respiratory distress syndrome
JP2007513180A (ja) 喘息の処置および予防
WO1996012470A9 (en) Treatment of pulmonary conditions associated with insufficient secretion of surfactant
CN102448498A (zh) 包括肺表面活性物质和类固醇的治疗组合
Garcia-Contreras et al. Aerosol treatment of cystic fibrosis
RU2748417C2 (ru) Стабильная фармацевтическая композиция, включающая восстановленную композицию легочного сурфактанта
US10124015B2 (en) Surfactant composition
TW201208690A (en) Lipid formulations
Yeates Surfactant aerosol therapy for nRDS and ARDS
WO2015061412A1 (en) Methods and compositions for promoting bronchioli dilatation
RS20170169A1 (sr) Poboljšana rekonstituisana kompozicija sufraktanta koja sadrži analoge sufraktanta proteina b (sp-b) i surfaktanta proteina c (sp-c)
Li Multi-component Microparticulate/nanoparticulate Dry Powder Inhalation Aerosols for Targeted Pulmonary Delivery
HK1109077B (en) Pulmonary surfactant formulations

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20100917

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20100917

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20120925

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20121221

A602 Written permission of extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A602

Effective date: 20130104

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20130123

A602 Written permission of extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A602

Effective date: 20130130

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20130220

A02 Decision of refusal

Free format text: JAPANESE INTERMEDIATE CODE: A02

Effective date: 20130723